---
schema_version: "secwatch.filing_event.v1"
accession: "0001583648-22-000061"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:08:00.350032+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pieris CMO Tim Demuth steps down effective Sept 30, 2022; severance of €265,125

## Summary
- Tim Demuth, M.D., Ph.D., Senior VP and CMO, mutually agreed to depart Pieris; effective September 30, 2022.
- Separation agreement includes 2 months base salary continuation and retirement contributions through Separation Date.
- Dr. Demuth will receive a pro-rata 2022 discretionary bonus and severance of €265,125 (~$270,427).
- Payments subject to release of claims and ongoing confidentiality obligations.

## SEC filing metadata
- accession: 0001583648-22-000061
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/0001583648-22-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/pirs-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001583648-22-000061
- JSON: https://secwatch.observer/filing/0001583648-22-000061.json
- Plain text: https://secwatch.observer/filing/0001583648-22-000061.txt

## Key facts
- Executive change
  Tim Demuth departed as Senior Vice President and Chief Medical Officer at PALVELLA THERAPEUTICS, INC..
  - Action: stepped down
  - Role: Senior Vice President and Chief Medical Officer
  source text: On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the " Company ") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/0001583648-22-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.